Globe Newswire (Fri, 26-Jul 2:31 PM ET)
GSK wins EU backing for RSV vaccine for those aged 50 – 59
Seeking Alpha News (Fri, 26-Jul 9:28 AM ET)
Agenus to Provide Second Quarter 2024 Financial Report and Corporate Update
Business Wire (Fri, 26-Jul 7:00 AM ET)
PRNewswire (Mon, 22-Jul 10:45 AM ET)
Business Wire (Thu, 18-Jul 7:00 AM ET)
Business Wire (Fri, 28-Jun 11:10 AM ET)
Cancer Therapy Evaluation Program Announces Availability of Botensilimab for Clinical Studies
Business Wire (Thu, 27-Jun 7:30 AM ET)
Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors
Business Wire (Mon, 17-Jun 7:00 AM ET)
Business Wire (Thu, 13-Jun 5:15 AM ET)
Agenus Announces Virtual Annual Shareholders Meeting
Business Wire (Tue, 4-Jun 7:30 AM ET)
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Agenus trades on the NASDAQ stock market under the symbol AGEN.
As of July 26, 2024, AGEN stock price climbed to $6.56 with 702,008 million shares trading.
AGEN has a beta of 5.14, meaning it tends to be more sensitive to market movements. AGEN has a correlation of 0.16 to the broad based SPY ETF.
AGEN has a market cap of $137.76 million. This is considered a Micro Cap stock.
Last quarter Agenus reported $28 million in Revenue and -$3.04 earnings per share. This fell short of revenue expectation by $-11 million and missed earnings estimates by -$.21.
In the last 3 years, AGEN stock traded as high as $135.80 and as low as $4.78.
The top ETF exchange traded funds that AGEN belongs to (by Net Assets): VTI, VXF, IWM, DWAS, VTWO.
AGEN has underperformed the market in the last year with a price return of -78.3% while the SPY ETF gained +21.0%. AGEN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -21.0% and -57.4%, respectively, while the SPY returned +8.5% and -2.2%, respectively.
AGEN support price is $5.43 and resistance is $6.50 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AGEN stock will trade within this expected range on the day.